Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Telesis Bio, Inc.

Telesis Bio focuses on advanced, rapid, and flexible automated RNA and DNA workflows to enable researchers to accelerate therapeutic discovery.

Metric
Company Name	Telesis Bio, Inc.
Symbol	TBIO
MSH ID	COM:TELESISBIO
Market	STOCKS
Sector	Healthcare
Industry	Medical - Devices
Country	US
Stage
Employee Count	127
Website	codexdna.com
LinkedIn
Founders

Metric
Market Cap	7.32M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	27.51M
Revenue (LTM)
Revenue (NTM)
Gross Profit	12.85M
EBITDA	-31.05M
Operating Income	-35.15M
Net Income	-47.72M
EPS	-1.60
Diluted EPS	-1.60
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.62
Operating Profit Margin	-1.23
EBITDA Margin	-1.13
Net Profit Margin	-1.27
Return on Equity	5.10
Return on Assets	-0.36
Return on Capital Employed	-0.46

COM:TELESISBIO

Telesis Bio

Last Close

0.37

14/02 20:00

Market Cap

7.32M

Beta: -

Volume Today

4.72K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.26
P/B Ratio	0.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.61
EV Multiple	0.85

Metric
Days Sales Outstanding	65.19
Days Payables Outstanding	77.12
Days Inventory Outstanding	137.27
Operating Cycle	210.44
Cash Conversion Cycle	125.33
Asset Turnover	0.39

Metric
Operating Cash Flow	-34.67M
Free Cash Flow	-36.65M
Cash Flow to Debt	-0.66
Operating Cash Flow/Sales	-1.09
Free Cash Flow Yield	-3.55

Metric
Cash & Equivalents	1.75M
Accounts Receivable	-1.33M
Inventory	4.03M
Goodwill	3.50M
Debt to Capitalization	0.52
Debt to Assets	0.48
Current Ratio	2.07
Quick Ratio	3.09

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.15
R&D to Revenue	0.60
SG&A to Revenue	0.77